Commission on cancer standards for lymph node sampling and oncologic outcomes after lung resection Journal Article


Authors: Resio, B. J.; Tan, K. S.; Skovgard, M.; Dycoco, J.; Adusumilli, P. S.; Bains, M. S.; Bott, M. J.; Downey, R. J.; Gray, K. D.; Huang, J.; Molena, D.; Park, B. J.; Rusch, V. W.; Sihag, S.; Rocco, G.; Jones, D. R.; Isbell, J. M.
Article Title: Commission on cancer standards for lymph node sampling and oncologic outcomes after lung resection
Abstract: Background: The newest Commission on Cancer standards recommend sampling 3 mediastinal and 1 hilar lymph node stations, 3 (N2) 1 (N1), for lung cancer resections. However, the relationship between the Commission on Cancer standards and outcomes has not been thoroughly investigated. Methods: A prospective institutional database was queried for clinical stage I-III lung resections before the implementation of the new standards. The relationship between the 3 (N2) 1 (N1) standard (“guideline concordant”) and outcomes (upstaging, complications, receipt of adjuvant therapy, locoregional/distant recurrence, and survival) was assessed with multivariable models and stratified by stage. Results: Of 9289 pulmonary resections, 3048 (33%) were guideline concordant and 6241 (67%) were not. Compared with nonconcordant, those that were guideline concordant had higher rates of nodal upstaging (21% vs 13%; odds ratio [OR], 1.32 [95% CI, 1.14-1.51]; P <.001) and in-hospital complications (34% vs 27%; OR, 1.17 [95% CI, 1.05-1.30]; P =.004) but similar adjuvant systemic therapy administration (19% vs 13%; OR, 1.09 [95% CI, 0.95-1.24]; P =.2; 98% chemotherapy). Locoregional and distant recurrences were not significantly improved with guideline concordance across clinical stage I, II, and III subsets. Overall survival was similar in clinical stages I and II, but improved survival was observed for guideline concordant clinical stage III patients (hazard ratio, 0.85 [95% CI, 0.74-0.97]; P =.02). Conclusions: Sampling 3 (N2) 1 (N1) was associated with increased upstaging and complications but not with decreased recurrence or mortality in clinical stage I or II patients. Survival was improved for concordant, clinical stage III patients. Further study is indicated to determine the ideal lymph node sampling strategy across heterogeneous lung cancer patients. © 2025 The Society of Thoracic Surgeons
Keywords: adult; cancer survival; controlled study; treatment outcome; aged; middle aged; cancer surgery; survival rate; retrospective studies; major clinical study; overall survival; mortality; cancer recurrence; systemic therapy; cancer patient; cancer staging; follow up; lymph node metastasis; antineoplastic agent; lymph node dissection; lymph nodes; lymphatic metastasis; neoplasm staging; prospective study; lymph node excision; prospective studies; cancer immunotherapy; neoplasm recurrence, local; lung lobectomy; lung neoplasms; pneumonectomy; cohort analysis; lung cancer; practice guideline; pathology; retrospective study; lung tumor; lung adenocarcinoma; tumor recurrence; adjuvant chemotherapy; lymph node; practice guidelines as topic; surgery; preoperative treatment; postoperative hemorrhage; forced expiratory volume; mediastinoscopy; video assisted thoracoscopic surgery; sampling; cumulative incidence; surgical margin; molecularly targeted therapy; clinical outcome; endobronchial ultrasonography; wedge resection; procedures; chylothorax; open surgery; recurrent laryngeal nerve injury; humans; human; male; female; article; squamous cell lung carcinoma; segmentectomy
Journal Title: Annals of Thoracic Surgery
Volume: 119
Issue: 2
ISSN: 0003-4975
Publisher: Elsevier Science, Inc.  
Date Published: 2025-02-01
Start Page: 308
End Page: 315
Language: English
DOI: 10.1016/j.athoracsur.2024.09.009
PUBMED: 39299477
PROVIDER: scopus
DOI/URL:
Notes: The MSK Cancer Center Support Grant (P30 CA008748) is acknowledge in the PDF -- Corresponding authors is MSK author: James M. Isbell -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Valerie W Rusch
    869 Rusch
  2. James Huang
    215 Huang
  3. Bernard J Park
    265 Park
  4. Matthew Bott
    136 Bott
  5. Robert J Downey
    254 Downey
  6. Joseph Dycoco
    46 Dycoco
  7. Manjit S Bains
    338 Bains
  8. David Randolph Jones
    418 Jones
  9. Daniela   Molena
    276 Molena
  10. Kay See   Tan
    244 Tan
  11. James Michael Isbell
    128 Isbell
  12. Smita Sihag
    98 Sihag
  13. Gaetano Rocco
    132 Rocco
  14. Katherine D. Gray
    26 Gray
  15. Benjamin Resio
    1 Resio